New tool to select liver transplant candidates for liver cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to improve the selection of patients with hepatocellular carcinoma (HCC) for liver transplant by using the HepatoPredict Prognostic Tool. This tool combines clinical and molecular criteria to better predict tumor behavior and aggressiveness, potentially allowing patients who do not meet the traditional Milan Criteria to be considered for transplantation. Patients aged 18 to 70 with specific tumor characteristics will undergo genomic analysis to determine their eligibility for liver transplant. The study will follow these patients for up to 60 months post-transplant to assess survival and recurrence of HCC.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Hepatocellular carcinoma associated with cirrhosis
* Ages between 18 and 70 years
* Total tumour volume below 500 cm3
* Total number of tumour lesions below 10
* Maximum individual tumour diameter below 10 cm

Exclusion Criteria:

* eligible under the "Milan Criteria"

Where it's running

• Centro Hepato-bilio-pancreático e de Transplantação do Hospital Curry Cabral
  Lisbon, Portugal Recruiting

Study contacts

• Principal investigator: Hugo Pinto-Marques, MD PhD — Centro Hospitalar Universitário de Lisboa Central
• Study coordinator: Hugo Pinto-Marques, MD PhD
• Email: hugo.marques3@chlc.min-saude.pt
• Phone: +351917302214

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Trimipramine with atezolizumab and bevacizumab for recurrent glioblastoma

  Researchers will try whether adding the antidepressant trimipramine to the immunotherapy atezolizumab plus bevacizumab helps people with recurrent glioblastoma.

  Recruiting at 7 sites Phase 2 Centre Hospitalier Universitaire Vaudois · Basel, Basel and 6 other locations · NCT07263438

• High Dose Rate Brachytherapy for Prostate Cancer Recurrence

  This study is testing if a special type of radiation treatment called High Dose Rate Brachytherapy can help men with prostate cancer that has come back after surgery feel better and have fewer side effects compared to regular radiation.

  Recruiting Clinica Universidad de Navarra, Universidad de Navarra · Pamplona, Foral Community of Navarre · NCT06982469

• Re-irradiation for local prostate cancer recurrences

  This study is testing if a special type of radiation therapy can safely help men whose prostate cancer has come back after previous treatment.

  Recruiting Phase 2 Maria Sklodowska-Curie National Research Institute of Oncology · Gliwice · NCT06201078

• Testing ONM-501 alone and with Cemiplimab for advanced solid tumors and lymphomas

  This study is testing a new treatment called ONM-501, both alone and with another drug called cemiplimab, to see if it can help people with advanced solid tumors and lymphomas who have run out of other treatment options.

  Recruiting at 5 sites Phase 1 OncoNano Medicine, Inc. · Los Angeles, California and 15 other locations · NCT06022029

• Re-irradiation for pelvic recurrences of gynecological cancers

  This study is testing if a special type of radiation therapy can help people with recurring gynecological cancers in the pelvis who have already had radiation treatment before.

  Recruiting CNAO National Center of Oncological Hadrontherapy · Pavia, Pv · NCT05457595

• Impact of surgical margin width on recurrence and survival in liver cancer from colorectal metastasis

  This study is testing whether having wider surgical margins during liver surgery for colorectal cancer spread can help patients live longer and have fewer recurrences of cancer.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT06934018

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.